SLC5A2 and hydrops fetalis: CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors) is a large multinational study that analyzing data from six countries reported a lower risk of hospitalization and mortality for HF with several SGLT2i (Kosiborod et al., 2018).